This list is based on the watchlists of people on Stock Events who follow B9A.STU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
The current price of B9A.STU is €29.92 EUR — it has decreased by -0.73% in the past 24 hours. Watch BioArctic AB stock price performance more closely on the chart.
What is BioArctic AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange BioArctic AB stocks are traded under the ticker B9A.STU.
Is BioArctic AB stock price growing?▼
B9A.STU stock has fallen by -1.25% compared to the previous week, the month change is a +0.54% rise, over the last year BioArctic AB has showed a +108.5% increase.
When is the next BioArctic AB earnings date?▼
BioArctic AB is going to release the next earnings report on May 20, 2026.
What were BioArctic AB earnings last quarter?▼
B9A.STU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was -0.05 EUR resulting in a +81.48% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does BioArctic AB have?▼
As of April 11, 2026, the company has 131 employees.